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Abstract
Background: Acinetobacter ursingii bacteremia is rarely reported. We investigated the incidence and clinical features
of A. ursingii bacteremia, performance of the identification system, and antimicrobial susceptibility of the isolates.
Acinetobacter ursingii bacteremia patients were compared with A. baumannii bacteremia patients.
Methods: In this 9-year retrospective study, A. ursingii was identified using 16S rRNA and 16S–23S rRNA internal
transcribed spacer sequence analysis. The performances of the Vitek 2, Phoenix, and matrix-assisted laser desorption
ionization time-of-flight (MALDI-TOF) mass spectrometer systems for identifying isolates were tested. Pulsed-field
gel electrophoresis (PFGE) was used to determine the clonality of the isolates. The minimal inhibitory concentrations of
the antimicrobials were determined using the Vitek 2 system.
Results: Nineteen patients were identified. Acinetobacter ursingii was noted in 1.5–5.2 % of all Acinetobacter bacteremia
cases. For the PFGE analysis, two isolates had smeared DNA, two had 93 % similarity, and 15 had similarity <80 %.
Among 16 patients with complete medical records, 10 (62.5 %) had no identifiable source of A. ursingii bacteremia.
Most patients (n = 12) had underlying malignant disease. Patients with A. ursingii bacteremia had lower Acute
Physiology and Chronic Health Evaluation II scores than those with A. baumannii bacteremia (median [interquartile
range], 17.1 [10.0–24.7] vs. 24.9 [14.6–35.1]). Patients with A. ursingii bacteremia were also less likely admitted to the
intensive care unit than patients with A. baumannii bacteremia (18.8 % vs 63.5 %, p value < 0.01). About half of the
patients with A. ursingii (50.8 %) and A. baumannii bacteremia (62.5 %) had received inappropriate antimicrobial therapy
within 48 h after bacteremia onset. However, patients with A. ursingii bacteremia had significantly lower 14-day (6.25 %
vs 29.8 %, p value = 0.04) and 28-day mortality rates (6.25 % vs 37.3 %, p value = 0.02) than patients with A. baumannii
bacteremia. Nine isolates (47.4 %) were correctly identified as A. ursingii and the other 10 isolates (52.6 %) were
incorrectly identified as A. lwoffii by the Vitek 2 system. The Phoenix system incorrectly identified all 19 isolates. The
MALDI-TOF mass spectrometer system correctly identified all 19 isolates. All the A. ursingii isolates were resistant or
showed intermediate susceptibility to ceftriaxone and ceftazidime, but were susceptible to levofloxacin and imipenem.
Conclusions: Acinetobacter ursingii is a rare pathogen that mostly caused primary bacteremia in patients with
malignancies. Patients with A. ursingii bacteremia had significantly lower disease severity and mortality rates than
patients with A. baumannii bacteremia.
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Background
The genus Acinetobacter comprises a heterogeneous
group of non-motile, aerobic, oxidase negative, non-
fermentative, gram-negative coccobacilli [1, 2]. They
are widespread in natural moist and hospital environ-
ments, and are associated with skin colonization of
hospitalized patients [3]. Although they were thought
to have low pathogenicity, the Acinetobacter species
have been recognized as opportunistic nosocomial
pathogens that mainly affect immune-compromised
patients and patients hospitalized in intensive care
units (ICUs) [4]. It has emerged as one of the most
troublesome pathogens for health care institutions
globally over the past 2 decades, owing to its increas-
ing prevalence and rapid development of drug
resistance.
The genus Acinetobacter comprises 39 genomic spe-
cies (http://www.bacterio.net/acinetobacter.html) [5].
While Acinetobacter species such as A baumannii, A.
nosocomialis, and A. pittii are frequently isolated as hu-
man pathogens [6–11]; other species, such as A. ursingii,
are rarely reported as pathogens [12, 13]. The low inci-
dence of A. ursingii infection may be further compli-
cated by the inaccurate identification tools used in
clinical laboratories. In this study, we aimed to describe
the incidence and clinical characteristics of A. ursingii
bacteremia, the performance of two phenotypic identifi-
cation systems and one matrix-assisted laser desorption
ionization time-of-flight (MALDI-TOF) mass spectrom-
eter, and the antimicrobial susceptibilities of the isolates.
Owing to the predominance of A. baumannii in clinical
settings, we also compared the clinical features of A.
ursingii and A. baumannii bacteremia.
Methods
Subjects
Patients who were admitted to the Taipei Veterans Gen-
eral Hospital (T-VGH) from January 2000 to December
2008, were included. T-VGH is a 2980-bed medical cen-
ter that serves about 120 thousand person-times pear
year. It serves not only veterans but also their families
and other individuals. The charts were reviewed from all
patients with symptoms and signs of infection who had
at least one positive blood culture for A. ursingii and A.
baumannii. If patients had two or more positive blood
cultures, only the first blood culture was included. The
source of infection was determined as recommended by
the Centers of Disease Control guidelines [14, 15]. Pa-
tients under 18 years of age and those with incomplete
medical records were excluded. The protocol was
approved by the T-VGH Institutional Review Board
(approval number: 2011-10-012IC), with a waiver for
informed consent.
Data collection
Medical records were reviewed to obtain clinical informa-
tion, including demographic characteristics; underlying
diseases; severity of illness; the presence of a ventilator,
central venous catheters, a nasogastric tube, or a Foley
catheter at the time of onset of bacteremia; intensive care
unit (ICU) hospitalization; and survival. Chronic kidney
disease was defined as an estimated glomerular filtration
rate <60 mL/min/1.73 m2. Neutropenia was defined as an
absolute neutrophil count of <0.5 × 109 neutrophils/L.
Recent surgery was defined as any operation performed
within 4 weeks prior to the onset of bacteremia. Shock
was defined as hypotension (systolic blood pressure
[SBP] <90 mmHg, mean arterial pressure <70 mmHg, or a
SBP decrease > 40 mmHg) with evidence of end organ
dysfunction. Bacteremia cases without a definite identified
source were defined as primary bacteremia. The severity
of illness was evaluated using the Acute Physiology and
Chronic Health Evaluation II (APACHE II) score [16]
within 24 h prior to bacteremia onset.
Appropriate antimicrobial therapy was defined as
administration of at least one antimicrobial agent to which
the causative pathogen was susceptible within 48 h of the
onset of bacteremia by an approved route and at a dosage
consistent with end organ(s) function. Antimicrobial
therapy that did not meet this definition was considered
inappropriate. Monotherapy with an aminoglycoside was
not considered the appropriate therapy. All-cause 14-day
and 28-day mortality rates were recorded.
Bacterial isolates, genotypic and phenotypic
identification, pulsed-field gel electrophoresis analysis,
and determination of antimicrobial minimal inhibitory
concentration
From January 2000 to December 2008, 616 clinical iso-
lates of Acinetobacter were isolated from blood samples
at T-VGH. All isolates were presumed to be Acinetobac-
ter species, as determined using phenotypic methods
with the 32GN system or the Vitek 2 system (bioMér-
ieux, Marcy l’Etoile, France). These isolates were in-
cluded in our study for further identification. A
multiplex-polymerase chain reaction method was then
used to identify A. baumannii at the genomic species
level [17]. Isolates belonging to non-A. baumannii spe-
cies were identified as A. ursingii using 16S rRNA gene
sequence [18] and confirmed by 16S-23S rRNA internal
transcribed spacer (ITS) sequence analysis [19]. Pulsed-
field gel electrophoresis (PFGE) was performed to deter-
mine the clonality of the isolates [20]. These A. ursingii
isolates were then used to determine the performance of
the Vitek 2 (bioMérieux), Phoenix (Becton Dickinson,
NJ, USA), and matrix-assisted laser desorption
ionization time-of-flight (MALDI-TOF) mass spectrom-
eter systems (Bruker Daltonics, Billerica, MA) in the
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identification of this species. The antimicrobial minimal
inhibitory concentrations (MICs) for the isolates were
determined by using the Vitek 2 system (bioMérieux).
The tested antimicrobials were ampicillin-sulbactam,
ceftazidime, ceftriaxone, cefepime, imipenem, amikacin,
gentamicin, ciprofloxacin, levofloxacin, and colistin. The
breakpoint interpretation was determined according to
the recommendations of the Clinical Laboratory Stan-
dards Institute (CLSI) [21].
Statistical analysis
To assess differences, the Student’s t-test or the Mann–
Whitney rank sum test was used to analyze continuous
variables, while the chi-square test with Yate’s correction
or Fisher’s exact test was used to compare discrete
variables. Time to mortality was analyzed using the
Kaplan–Meier survival analysis and the long-rank test.
A p-value <0.05 was considered statistically signifi-
cant. All analyses were processed with the Statistical
Package for the Social Sciences (SPSS) software ver-
sion 18.0 (SPSS, Chicago, IL, USA).
Results
Incidence and clinical features of A. ursingii bacteremia
During the study period, 616 patients were found to
have Acinetobacter species bacteremia and were included
in our study. Among the isolates, 19 (3.1 %) were identi-
fied as A. ursingii by16S rRNA gene sequence analysis
and confirmed by ITS sequence analysis (similarity: 98-
99 % to reference strains) and 252 (40.9 %) as A. bau-
mannii. For the PFGE analysis, two isolates had smeared
DNA, two had 93 % similarity, and 15 had similarity less
than 80 % (Fig. 1). The annual incidence of A. ursingii
among Acinetobacter species bacteremia in this study
was 1.5–5.2 %.
The clinical data of the first three A. ursingii
bacteremia patients were incomplete and they were
therefore excluded from further analysis. The compari-
son of demographic features, underlying diseases, APA-
CHE II scores, and outcomes of A. ursingii and A.
baumannii bacteremia patients included in this study
are summarized in Table 1.
The gender of the patients with A. ursingii bacteremia
was similar, while most patients with A. baumannii
bacteremia were male. Primary bacteremia was mostly
noted among those with A. ursingii infection (62.5 %),
while respiratory tract infection (51.6 %) was the major
source of A. baumannii bacteremia. The comorbidity
of these two groups was similar, except that A. ursin-
gii bacteremia tended to occur in patients with
hematologic malignancies (p value < 0.01) or neutro-
penia who had undergone chemotherapy in the past
month (p value <0.01). Patients with A. ursingii
bacteremia had lower APACHE II scores (p value < 0.01),
and less often acquired infection in the intensive care unit
than patients with A. baumannii bacteremia (p value <
0.01). Consequently, patients with A. ursingii bacteremia
underwent fewer invasive produces, including endo-
tracheal tubing or tracheostomy (p value < 0.01), naso-
gastric tubing (p value < 0.01), and ventilator support
(p value = 0.02).
About half of the patients with A. ursingii (50.8 %) and
A. baumannii bacteremia (62.5 %) had received inappro-
priate antimicrobial therapy within 48 h of the onset of
bacteremia. However, the 14-day (p value = 0.04) and 28-
day (p value = 0.02) mortality rates of the A. ursingii
group were significantly lower than those of the A. bau-
mannii group. The Kaplan-Meier survival curves also
showed that patients with A. ursingii had a higher cumu-
lative survival rate than those with A. baumannii
(Fig. 2).
Fig. 1 Pulse-field gel electrophoresis patterns of the Acinetobacter ursingii isolates
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Table 1 Demographic data, clinical features, and outcomes of patients with Acinetobacter ursingii and Acinetobacter baumannii
bacteremia
Acinetobacter ursingii (n = 16) Acinetobacter baumannii (n = 252) p value
n (%)/median (Q1-Q3)/mean ± S.D.
Gender, male 7 (43.8 %) 183 (72.6 %) 0.01
Age in years (median, IQR) 66.6 (50.0–83.2) 68.7 (52.6–84.9) 0.61
Source
Respiratory tract 4 (25 %) 130 (51.6 %) 0.04
Intra-abdominal 1 (6.25 %) 18 (7.1 %) 0.89
Urinary tract 0 19 (7.5 %) 0.25
Intravenous device 0 12 (4.8 %) 0.37
Wound 0 10 (4.0 %) 0.42
Other 1 (6.25 %) 13 (5.2 %) 0.85
Unknown 10 (62.5 %) 50 (19.8 %) <0.01
Comorbidity
Diabetes mellitus 2 (12.5 %) 66 (26.2 %) 0.22
Hypertension 7 (43.8 %) 78 (31.0 %) 0.29
Coronary artery disease 2 (12.5 %) 30 (11.9 %) 0.94
Congestive heart failure 3 (18.8 %) 21 (8.3 %) 0.16
Chronic obstructive pulmonary disease 2 (12.5 %) 40 (15.9 %) 0.72
Cerebral vascular disease 2 (12.5 %) 47 (18.7 %) 0.54
Chronic kidney disease 3 (18.8 %) 47 (18.7 %) 0.99
End stage renal disease 1 (6.3 %) 11 (4.4 %) 0.72
Alcoholism 1 (6.3 %) 22 (8.7 %) 0.73
Malignancy 12 (75 %) 88 (34.9 %) <0.01
Solid malignancy 7 (43.8 %) 69 (27.4 %) 0.16
Hematologic malignancy 5 (31.3 %) 19 (7.5 %) <0.01
Neutropenia 4 (25.0 %) 9 (3.6 %) <0.01
Trauma 0 8 (3.2 %) 0.47
Surgery in 1 month 4 (25 %) 88 (34.92 %) 0.42
Procedure
Ventilator 4 (25 %) 137 (54.4 %) 0.02
Endotracheal tube or tracheostomy 4 (25 %) 187 (74.2 %) <0.01
Central venous catheter 6 (37.5 %) 130(51.6 %) 0.27
Artery line 6 (37.5 %) 52 (20.6 % 0.26
Foley catheter 6 (37.5 %) 157 (62.3 %) 0.05
Nasogastric tube 6 (37.5 %) 180 (71.4 %) <0.01
Thoracic drain 0 9 (3.6 %) 0.44
Hemodialysis 1 (6.25 %) 16 (6.35 %) 0.99
Total parental nutrition 1 (6.25 %) 24 (9.5 %) 0.66
Other
Chemotherapy 9 (56.3 %) 28 (11.1 %) <0.01
Steroid use 3 (18.8 %) 69 (27.4 %) 0.45
Shock 2 (12.5 %) 54 (21.4 %) 0.39
Acquired in ICU 3 (18.8 %) 160 (63.5 %) <0.01
APACHE II score (median, IQR) 17.1 (10.0–24.7) 24.9 (14.6–35.1) <0.01
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Identification
The identifications of these 19 clinical isolates of A.
ursingii under the Vitek 2, Phoenix, and MALDI-TOF
mass spectrometer systems are listed in Table 2. Accord-
ing to the ID-GNB card of the Vitek 2 system, 9 isolates
(47.4 %) were correctly identified as A. ursingii. The
other 10 isolates (52.6 %) were incorrectly identified as
A. lwoffii. The Phoenix system incorrectly identified all
19 isolates. Among them, 15 isolates (78.9 %) were mis-
identified as Alcaligenes faecalis, 3 isolates (15.8 %) as A.
lwoffii/haemolyticus, and 1 isolate (5.3 %) as Moraxella
species. All the 19 isolates (100 %) were correctly identi-
fied as A. ursingii by using MALDI-TOF mass spectrom-
eter analysis.
Antimicrobial susceptibility
The antimicrobial susceptibility results of the 19 isolates
are summarized in Table 3. All the A. ursingii isolates
were resistant or had intermediate susceptibility to cef-
triaxone and ceftazidime, and all were susceptible to
levofloxacin and imipenem. About half of the A. ursingii
isolates were resistant or had intermediate susceptibility
to ciprofloxacin (47.4 %) and cefepime (42.1 %). A small
number of the isolates were resistant or had intermedi-
ate susceptibility to amikacin (10.5 %), gentamicin
(15.8 %), ampicillin-sulbactam (21.1 %), and colistin
(15.8 %).
Discussion
Acinetobacter ursingii is a rare pathogen that mostly
causes bacteremia in patients with hematologic malig-
nancies. In this study, most cases were of primary
bacteremia, and patients had milder disease severity and
underwent fewer invasive procedures than patients with
A. baumannii bacteremia. Although more than half of
the patients with A. ursingii and A. baumannii
bacteremia had undergone inappropriate antimicrobial
therapy within 48 h of the onset of bacteremia, the
14-day and 28-day mortality rates of patients with A.
ursingii bacteremia were significantly lower than those
of patients with A. baumannii bacteremia.
As in previous studies [12, 22], a low incidence of A.
ursingii bacteremia was noted in our study (1.5–5.2 %
during the study period). Compared to the risk factors
and clinical characteristics of patients with A. baumannii
bacteremia, patients with A. ursingii bacteremia are be-
lieved to be more immunosuppressed than patients with
A. baumannii bacteremia, due to the higher concurrence
rate in patients with hematologic malignancy, neutro-
penia, and chemotherapy treatment. Compared to the
condition of patients with A. baumannii bacteremia, that
of patients with A. ursingii seemed less severe, as indi-
cated by lower APACHE II scores, fewer ICU admissions
and invasive procedures, and lower mortality rates. The
results indicated a lower virulence of A. ursingii, and this
may account for the lower incidence of A. ursingii
bacteremia.
It is unclear why most of the A. ursingii cases were
primary bacteremia without an obvious source of infec-
tion. Among the patients with A. ursingii bacteremia,
central venous catheters were placed in 6 patients
(37.5 %), arterial catheters in 6 patients (37.5 %), and
total parenteral nutrition in 1 patient (6.25 %). One pa-
tient (6.25 %) required dialysis and 4 patients (25 %)
needed ventilator support at the onset of bacteremia.
Table 1 Demographic data, clinical features, and outcomes of patients with Acinetobacter ursingii and Acinetobacter baumannii
bacteremia (Continued)
Appropriate antimicrobial therapy 10 (62.5 %) 128 (50.8 %) 0.36
Hospitalized days (median, IQR) 28 (13–60) 39 (18–73.5) 0.56
Mortality
14-day mortality 1 (6.25 %) 75 (29.8 %) 0.04
28-day mortality 1 (6.25 %) 94 (37.3 %) 0.02
The data were presented in number and percentage, unless indicated otherwise. IQR interquartile range, ICU intensive care unit, APACHE II Acute Physiology and
Chronic Health Evaluation II
A. ursingii
A. baumannii
Fig. 2 The Kaplan-Meier survival curves of patients with bacteremia
caused by Acinetobacter ursingii and Acinetobacter baumannii. The
30-day mortality rate of A. ursingii bacteremia was significantly lower
than that of A. baumannii bacteremia (p-value = 0.0352)
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The intravascular device may serve as a port of entry for
A. ursingii bacteremia.
Phenotypic schemes are generally insufficient to accur-
ately identify the Acinetobacter isolates at the species
level [23–25]. Phenotypic identification by commercial
colorimetric systems is also unsatisfactory [6, 12, 26, 27].
Using systems such as the Vitek 2, API20NE systems
(bioMérieux, Marcy l’Etoile, France) and the Phoenix
system, the clinically relevant species of the A.
calcoaceticus–A. baumannii complex are frequently
uniformly identified as A. baumannii, and many other
species are not identified [6, 12, 26, 27]. On comparison,
the Vitek 2 systems in our study could correctly identify
about half of the isolates, and Phoenix systems failed to
correctly identify any. Protein fingerprinting using a
MALDI-TOF mass spectrometer is a promising molecular
method for rapid identification of Acinetobacter species
with high-throughput capability. A previous study
Table 2 Identifications obtained with the Phoenix, Vitek 2 systems, and matrix-assisted laser desorption ionization time-of-flight mass
spectrometer for the Acinetobacter ursingii isolates
No. Phoenix (confidence value) VITEK 2 ID-GNB card (confidence value) MALDI-TOF (confidence value)
1 Moraxella species (97 %) Acinetobacter lwoffii (94 %) Acinetobacter ursingii (99.9 %)
2 Acinetobacter lwoffii/haemilyticus (90 %) Acinetobacter lwoffii (94 %) Acinetobacter ursingii (99.9 %)
3 Alcaligenes faecalis (95 %) Acinetobacter ursingii (98 %) Acinetobacter ursingii (99.9 %)
4 Alcaligenes faecalis (95 %) Acinetobacter ursingii (97 %) Acinetobacter ursingii (99.9 %)
5 Acinetobacter lwoffii/haemolyticus (90 %) Acinetobacter lwoffii (97 %) Acinetobacter ursingii (99.9 %)
6 Alcaligenes faecalis (90 %) Acinetobacter lwoffii (95 %) Acinetobacter ursingii (99.9 %)
7 Alcaligenes faecalis (95 %) Acinetobacter ursingii (93 %) Acinetobacter ursingii (99.9 %)
8 Alcaligenes faecalis (90 %) Acinetobacter ursingii (93 %) Acinetobacter ursingii (99.9 %)
9 Alcaligenes faecalis (96 %) Acinetobacter ursingii (93 %) Acinetobacter ursingii (99.9 %)
10 Alcaligenes faecalis (98 %) Acinetobacter ursingii (94 %) Acinetobacter ursingii (99.9 %)
11 Alcaligenes faecalis (98 %) Acinetobacter lwoffii (91 %) Acinetobacter ursingii (99.9 %)
12 Acinetobacter lwoffii/haemolyticus (90 %) Acinetobacter lwoffii (93 %) Acinetobacter ursingii (99.9 %)
13 Alcaligenes faecalis (98 %) Acinetobacter lwoffii (91 %) Acinetobacter ursingii (99.9 %)
14 Alcaligenes faecalis (98 %) Acinetobacter lwoffii (90 %) Acinetobacter ursingii (99.9 %)
15 Alcaligenes faecalis (90 %) Acinetobacter lwoffii (95 %) Acinetobacter ursingii (99.9 %)
16 Alcaligenes faecalis (95 %) Acinetobacter ursingii (96 %) Acinetobacter ursingii (99.9 %)
17 Alcaligenes faecalis (98 %) Acinetobacter ursingii (93 %) Acinetobacter ursingii (99.9 %)
18 Alcaligenes faecalis (95 %) Acinetobacter ursingii (94 %) Acinetobacter ursingii (99.9 %)
19 Alcaligenes faecalis (95 %) Acinetobacter lwoffii (95 %) Acinetobacter ursingii (99.9 %)
Table 3 Antimicrobial susceptibility profiles of the 19 Acinetobacter ursingii isolates
No. of A. ursingii isolates
S I R I + R MIC range MIC50 MIC90
Ampicillin-Sulbactam 15 3 1 21.1 % ≤2–16 ≤2 16
Ceftazidime 0 3 16 100.0 % 16–≥ 64 ≥64 ≥64
Ceftriaxone 0 10 9 100.0 % 16–≥ 64 32 ≥64
Cefepime 11 0 8 42.1 % 4–32 8 32
Imipenem 19 0 0 0.0 % ≤0.25 ≤0.25 ≤0.25
Amikacin 17 0 2 10.5 % ≤2–≥ 64 ≤2 ≤2
Gentamicin 16 1 2 15.8 % ≤1–≥ 16 ≤1 8
Ciprofloxacin 10 7 2 47.4 % ≤0.25– ≥ 4 1 2
Levofloxacin 19 0 0 0.0 % ≤0.12–1 0.5 1
Colistin 16 0 3 15.8 % ≤0.5–4 0.5 4
S susceptible, I intermediate susceptible, R resistant
Minimal inhibitory concentrations (MICs) are given in milligrams per liter (mg/L)
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revealed a 72.4 % correct identification rate for Acineto-
bacter species by using MALDI-TOF mass spectrometer
[28]. The correct rate of A. ursingii identification was
93.3 % in that study. As the database of the MALDI-TOF
mass spectrometer expanded, 100 % of the A. ursingii iso-
lates were correctly identified in our study.
In our study, all the A. ursingii isolates exhibited high
resistance to third- and fourth-generation cephalospo-
rins. These results suggest the presence of some ex-
tended spectrum β-lactamase, which deserves further
study. More than 80 % of the A. ursingii isolates were
susceptible to imipenem, levofloxacin, amikacin, genta-
micin, and colistin. While comparing the antimicrobial
susceptibility of the A. ursingii isolates in our study with
the isolates reported by Cattoir in 2006 [12], the resist-
ance rate to ciprofloxacin, gentamicin, amikacin, and co-
listin seemed higher. Further studies are needed to
elucidate the mechanisms underlying antimicrobial
resistance.
Conclusion
In conclusion, A. ursingii is a rare pathogen with a low
mortality rate. This pathogen mostly causes primary
bacteremia in patients with malignancies.
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